Migraine frequency dropped from 10.4 to 4.6 per month (55% reduction, p < 0.0001) in 121 patients using medical cannabis — strong observational signal but no placebo control.
Migraine patients considering cannabis; neurologists evaluating cannabinoid therapy; anyone interested in the cannabis-migraine evidence.
55% — reduction in monthly migraine frequency with medical cannabis
The Backstory
Migraine affects 39 million Americans and roughly 1 billion people worldwide. It's not just a headache — it's a neurological event involving cortical spreading depression, trigeminal nerve activation, and inflammatory cascades that can produce hours of disabling pain, nausea, light sensitivity, and cognitive dysfunction. The available preventive medications (beta-blockers, topiramate, amitriptyline, newer CGRP inhibitors) work for some patients but leave many others cycling through drug after drug without adequate relief.
Meanwhile, migraine patients have been using cannabis for centuries. The compound appears in historical medical texts for headache going back to Assyrian manuscripts from 2000 BCE. But modern medicine had virtually no data on whether it actually works — until Danielle Rhyne's team at a Colorado specialty clinic decided to look at what was happening in their own patient records.
The Study
This wasn't a randomized trial. It was a retrospective chart review — the research equivalent of looking back at what already happened. Rhyne's team pulled medical records from 121 adults with a primary migraine diagnosis who had been recommended medical marijuana at two Colorado clinics between 2010 and 2014. Every patient had at least one follow-up visit documenting migraine frequency before and after starting cannabis.
10.4 → 4.6
monthly migraines — the average frequency before and after medical cannabis use in 121 patients. A 55% reduction in migraine frequency (p < 0.0001).
For context, the most effective migraine preventive medications (topiramate, propranolol) typically reduce migraine frequency by 40-50% in responders. This effect size is comparable — though the study design is much weaker.
Rhyne et al. (2016), Pharmacotherapy 36(5):505-510
The Breakdown
The results weren't uniform. Different patients used cannabis differently, and the outcomes varied accordingly.
Patient Outcomes
How 121 Migraine Patients Responded to Cannabis
85%
Decreased frequency
103 of 121 patients
12%
Complete resolution
migraines eliminated entirely
12%
No change
cannabis didn't help
12%
Negative effects
primarily somnolence from edibles
Rhyne et al. (2016), Pharmacotherapy
The form of cannabis mattered. Patients who used inhaled cannabis (smoked or vaporized) reported better acute migraine relief — they could abort an attack in progress. Patients who used edibles reported more preventive benefit but also more side effects, particularly somnolence. Most patients ended up using both: daily edibles or oils for prevention, inhaled cannabis for acute attacks.
Inhaled (Smoked/Vaporized)
- Faster onset (minutes vs. 1-2 hours)
- Preferred for acute migraine abortion
- Easier to titrate dose in real-time
- Fewer reports of somnolence
- Potential respiratory concerns with long-term use
Better for acute attacks
Edibles/Oils
- Slower onset but longer duration
- Preferred for daily prevention
- More consistent dosing
- More somnolence reported
- 11-OH-THC metabolite produces stronger effects
Better for prevention
Rhyne et al. (2016)
The Endocannabinoid Connection
Rhyne's findings are consistent with Ethan Russo's clinical endocannabinoid deficiency hypothesis. If migraine involves deficient endocannabinoid signaling — as suggested by CSF studies showing reduced anandamide in chronic migraineurs — then supplementing with plant cannabinoids should, in theory, help.
The serotonergic mechanism adds another layer. Cannabinoids modulate serotonin receptors in the central nervous system — the same target as triptans, the gold-standard acute migraine treatment. THC acts on 5-HT1A and 5-HT2A receptors, potentially affecting the same pathways that migraine drugs target through a different pharmacological route.
This isn't proof that cannabis works for migraine through endocannabinoid supplementation or serotonin modulation. But it's biological plausibility that makes the clinical observations harder to dismiss.
The Limitations — And They're Significant
Reasons for Confidence
moderate- Large effect size (55% reduction) is difficult to explain by placebo alone
- Consistent with historical use of cannabis for headache spanning millennia
- Consistent with known pharmacology — cannabinoid-serotonin interactions in migraine pathways
- Consistent with endocannabinoid deficiency data (CSF anandamide, platelet studies)
- 85% response rate is higher than most migraine preventives
Reasons for Caution
strong- Retrospective chart review — no randomization, no blinding, no placebo group
- Self-selected patients who chose cannabis (motivation bias)
- Regression to the mean — patients seek treatment when migraines are worst
- No control for natural disease fluctuation
- Cannabis is difficult to blind — patients know they're getting it
- Only 121 patients at two clinics in one state
- No standardized cannabis products — patients used whatever was available
Rhyne et al. (2016)
The absence of a placebo group is the critical weakness. Chronic pain and migraine have notoriously high placebo response rates — 30% or more in some trials. Patients who actively seek cannabis treatment and believe it will help are precisely the population most likely to experience placebo benefit. The 55% reduction could be partly or largely placebo-driven.
But "partly placebo-driven" isn't "not real." Even if half the effect is placebo, a 25% real reduction in migraine frequency would still be clinically meaningful for patients who've exhausted other options.
What Happened Next
Rhyne's study launched a wave of migraine-cannabis research. Subsequent studies have generally confirmed the association:
- Larger surveys have replicated the self-reported benefit
- Laboratory studies have documented cannabinoid effects on trigeminovascular pathways
- The CECD framework has gained additional supporting evidence
- But as of 2026, no large randomized controlled trial of cannabis for migraine prevention has been published
This remains one of the most frustrating evidence gaps in cannabis medicine. Millions of migraine patients use cannabis. The biological plausibility is strong. The observational data is consistent. And yet the gold-standard evidence — a large, placebo-controlled RCT — doesn't exist.
For migraine patients considering cannabis, our guide on cannabis and migraines covers the full evidence landscape, including what to try, what to avoid, and how to talk to your neurologist about it.
Related Research
Cannabis and Migraine: The Evidence Chain
From deficiency hypothesis to patient outcomes.
Clinical endocannabinoid deficiency (CECD)
Russo (2004)
The hypothesis that migraine involves endocannabinoid deficiency — the theoretical foundation for why cannabis should work
CECD reconsidered
Russo (2016)
CSF anandamide data in chronic migraineurs — biochemical evidence supporting the deficiency model
CECD at twenty years
Russo (2024)
The twenty-year reassessment — migraine remains the condition with the strongest CECD evidence
Cannabinoids for Medical Use
Whiting et al. (2015)
The comprehensive review — limited evidence for headache/migraine specifically, highlighting the need for better trials
THC and CBD have opposite brain effects
Bhattacharyya et al. (2010)
CBD may counteract THC's side effects while preserving analgesic benefit — relevant to optimal migraine treatment ratios
Does cannabis prevent migraines?
This retrospective study found a 55% reduction in monthly migraine frequency (10.4 to 4.6) in 121 patients using medical cannabis. However, this is observational data without a placebo group — the true effect size is likely smaller than 55% after accounting for placebo response and regression to the mean. No randomized trial has been published. The biological plausibility is strong (endocannabinoid system involvement in migraine pathways), but the clinical evidence remains preliminary. See our full guide on cannabis for migraine.
Should I smoke or eat cannabis for migraines?
This study found that inhaled cannabis worked better for aborting acute attacks (fast onset), while edibles worked better for daily prevention (sustained effect). Most patients used both. The tradeoffs: inhaled cannabis acts within minutes but carries respiratory risks; edibles are harder to dose but provide longer coverage. If considering cannabis for migraines, discuss with your healthcare provider and start with low doses.
Is this study reliable?
It's suggestive but not conclusive. A retrospective chart review at two clinics with 121 self-selected patients is a low tier of evidence. There's no placebo group, no randomization, and no blinding. The results are consistent with other observational data and with the known pharmacology — but they don't constitute proof. Randomized trials are needed and overdue.
What the researchers found
Migraine frequency decreased from 10.4 to 4.6 headaches per month (p < 0.0001) with medical cannabis. 85% reported decreased frequency. 12% achieved complete migraine resolution.
Why it matters
First study documenting migraine frequency outcomes in patients using medical cannabis. Consistent with endocannabinoid deficiency hypothesis and historical use of cannabis for headache. Highlights the enormous evidence gap — no RCT exists.
How the study worked
Retrospective chart review of 121 adults with primary migraine diagnosis recommended medical marijuana at two Colorado specialty clinics between 2010-2014. Migraine frequency documented before and after cannabis initiation.
Who was studied
121 adults with primary migraine diagnosis at two Colorado specialty clinics (2010-2014)
What this study cannot tell us
Retrospective design, no placebo group, no randomization, no blinding. Self-selected patients. Regression to the mean. No standardized cannabis products. Only 121 patients at two clinics. High placebo response expected in migraine populations.
How to read the evidence
Retrospective chart review without a control group — low-to-moderate evidence level. The effect size is large and consistent with pharmacological mechanisms, but placebo response could account for a significant portion of the observed benefit.
When this study was published
Published 2016 — no large RCT has followed. Remains the primary clinical reference for cannabis and migraine frequency.
The bigger picture
Migraine is the condition with the strongest theoretical rationale for cannabis treatment (CECD hypothesis, serotonin modulation, trigeminovascular pathway effects) and consistent observational data — but the randomized trial evidence remains absent.
Questions still open
- What is the optimal THC:CBD ratio for migraine prevention? Does inhaled vs. oral administration produce different long-term outcomes? Would a placebo-controlled trial replicate this magnitude of effect?
Common questions
Read the original research
Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population.
Pharmacotherapy, 36(5), 505-510
Citation
Rhyne, Danielle N; Anderson, Sarah L; Gedde, Margaret; Borgelt, Laura M. (2016). Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population.. Pharmacotherapy, 36(5), 505-510. https://doi.org/10.1002/phar.1673